Adjuvant Atezolizumab/mFOLFOX6 Improves DFS in Stage III dMMR Colon Cancer
Adding atezolizumab to adjuvant FOLFOX significantly improves disease‑free survival for patients with stage III mismatch‑repair‑deficient colon cancer.
Adding atezolizumab to adjuvant FOLFOX significantly improves disease‑free survival for patients with stage III mismatch‑repair‑deficient colon cancer.
This study demonstrates that incorporating an immune checkpoint inhibitor into standard adjuvant chemotherapy enhances disease‑free survival in a specific biomarker‑positive subset of stage III colorectal cancer patients, potentially establishing a new standard of care for this population.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics